The Technical Analyst
Forward Pharma A/S [FWP]
Exchange: NASDAQ Capital Market Sector: Healthcare Industry: Biotechnology
Forward Pharma A/S Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $1.950
/ 27 des 2022 @ 16:00
| RATING 2023-02-27 |
|---|
| B+ |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/20 | 4/20 | 2/21 | 4/21 | 2/22 | 4/22 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | n/a | n/a | n/a | n/a | n/a | n/a |
| Asset | n/a | n/a | n/a | n/a | n/a | |
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.751 - 2.15 ( +/- 10.21%) |
| ATR Model: 14 days |
Forecast:
01:40 - $2.43
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.950 (0.00% ) |
| Volume | 0.0434 mill |
| Avg. Vol. | 0.0098 mill |
| % of Avg. Vol | 440.46 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For FWP
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
FWP
Forward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.
Latest Press Releases
2021-09-06 10:21:00 - Press Release
Forward Pharma Announces The Decision Of The Technical Board Of Appeal Of The European Patent Office In The Ep2801355 Appeal Hearing
Copenhagen, denmark, sept. 06, 2021 (globe newswire) -- forward pharma a/s (nasdaq:fwp) (“we,” “forward” or the “company”), today announced that the technical board of appeal (the “tba”) of the european patent office (the “epo”) has dismissed forward's appeal of the previous decision of the epo opposition division to revoke the ep2801355 patent (the “'355 patent”) following the oral hearing.
2021-04-14 16:40:00 - Press Release
Forward Pharma Reports Financial And Operational Results From The Year Ended December 31, 2020
Copenhagen, denmark, april 14, 2021 (globe newswire) -- forward pharma a/s (nasdaq:fwp) (“we,” “forward” or the “company” and, together with its subsidiaries, the “group”), today reported consolidated financial results for the year ended december 31, 2020. our net loss for the year ended december 31, 2020 was $6.4 million, or $0.07 per share, versus a net loss of $4.2 million, or $0.04 per share for the year ended december 31, 2019. our research and development and general and administrative costs decreased from $5.3 million for the year ended december 31, 2019 to $3.4 million for the year ended december 31, 2020. our net loss for the year ended december 31, 2020 was unfavorably impacted by a significant non-cash foreign exchange loss of $3...
2021-01-12 16:30:00 - Press Release
Forward Pharma Announces Rescheduling Of The Ep2801355 Appeal Hearing To September 6, 2021 Due To Covid-19 Restrictions
Copenhagen, denmark, jan. 12, 2021 (globe newswire) -- forward pharma a/s (nasdaq:fwp) (“we,” “forward” or the “company”), today announced that due to ongoing precautionary measures against the spread of the novel coronavirus (“covid-19”), the technical board of appeal (the “tba”) of the european patent office (the “epo”) again has rescheduled the oral hearing of the appeal against the decision of the opposition division that revoked the ep2801355 patent (the “'355 patent”). the new hearing date is set for september 6, 2021.
2020-10-02 00:00:00 - Press Release
Global Precision Medicine Market 2020-2030: Focus On Ecosystem, Technology, Application, And Competitive Landscape - Researchandmarkets.com
The
2020-09-25 00:00:00 - Press Release
Covid-19 Recovery Analysis: Crushing Equipment Market | Use Of Artificial Sand For Construction Work To Boost The Market Growth | Technavio
The global crushing equipment market will grow by $ 281.30 mn during 2020-2024
Latest News
2021-09-07 06:08:50 - Benzinga
Why is Forward Pharma Stock Plunging During Premarket Tuesday?
The stock price of Forward Pharma A/S (NASDAQ: FWP) fell by almost 20% during the premarket. Investors are responding negatively to the Technical Board of Appeal (TBA) of the European Patent Office (EPO), dismissing Forward's appeal to revoke the EP2801355 patent (355 patent) following the oral hearing.
2021-09-07 04:34:12 - Pulse2
FWP Stock: Over 20% Decrease Pre-Market Explanation
The stock price of Forward Pharma A/S (NASDAQ:FWP) fell by over 20% pre-market. This is why it happened.
2021-09-06 10:21:00 - GlobeNewsWire
Forward Pharma Announces the Decision of the Technical Board of Appeal of the European Patent Office in the EP2801355 Appeal Hearing
COPENHAGEN, Denmark, Sept. 06, 2021 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we,” “Forward” or the “Company”), today announced that the Technical Board of Appeal (the “TBA”) of the European Patent Office (the “EPO”) has dismissed Forward's appeal of the previous decision of the EPO Opposition Division to revoke the EP2801355 patent (the “'355 patent”) following the oral hearing.
2021-04-14 16:40:00 - GlobeNewsWire
Forward Pharma Reports Financial and Operational Results from the Year Ended December 31, 2020
COPENHAGEN, Denmark, April 14, 2021 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“We,” “Forward” or the “Company” and, together with its subsidiaries, the “Group”), today reported consolidated financial results for the year ended December 31, 2020. Our net loss for the year ended December 31, 2020 was $6.4 million, or $0.07 per share, versus a net loss of $4.2 million, or $0.04 per share for the year ended December 31, 2019. Our research and development and general and administrative costs decreased from $5.3 million for the year ended December 31, 2019 to $3.4 million for the year ended December 31, 2020. Our net loss for the year ended December 31, 2020 was unfavorably impacted by a significant non-cash foreign exchange loss of $3...
2021-01-12 16:30:00 - GlobeNewsWire
Forward Pharma Announces Rescheduling of the EP2801355 Appeal Hearing to September 6, 2021 due to COVID-19 Restrictions
COPENHAGEN, Denmark, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we,” “Forward” or the “Company”), today announced that due to ongoing precautionary measures against the spread of the novel coronavirus (“COVID-19”), the Technical Board of Appeal (the “TBA”) of the European Patent Office (the “EPO”) again has rescheduled the oral hearing of the appeal against the decision of the Opposition Division that revoked the EP2801355 patent (the “'355 Patent”). The new hearing date is set for September 6, 2021.
2020-10-22 02:54:55 - https://www.thelincolnianonline.com
Goldman Sachs Group Upgrades Chr. Hansen Holding A/S (OTCMKTS:CHYHY) to Neutral
Chr. Hansen Holding A/S (OTCMKTS:CHYHY) was upgraded by research analysts at Goldman Sachs Group from a “sell” rating to a “neutral” rating in a report issued on Tuesday, The Fly reports. A number of other brokerages have also issued reports on CHYHY. JPMorgan Chase & Co. restated an “underweight” rating on shares of Chr. Hansen […]
2020-10-21 03:14:41 - https://www.thelincolnianonline.com
Chr. Hansen Holding A/S (OTCMKTS:CHYHY) Given Consensus Recommendation of “Hold” by Analysts
Chr. Hansen Holding A/S (OTCMKTS:CHYHY) has been assigned a consensus rating of “Hold” from the eight ratings firms that are covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a sell recommendation and five have given a hold recommendation to the company. A number of equities analysts have recently commented […]
2020-10-16 00:00:00 - investing
Denmark stocks higher at close of trade; OMX Copenhagen 20 up 0.65%
2020-10-15 05:44:48 - https://www.thelincolnianonline.com
Analysts Set Ascendis Pharma A/S (NASDAQ:ASND) Price Target at $176.50
Shares of Ascendis Pharma A/S (NASDAQ:ASND) have earned a consensus rating of “Buy” from the fourteen research firms that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and twelve have given a buy recommendation to the company. The average 12-month […]
2020-10-14 08:14:41 - https://www.thelincolnianonline.com
Nuveen Asset Management LLC Has $1.79 Million Position in Ascendis Pharma A/S (NASDAQ:ASND)
Nuveen Asset Management LLC lowered its position in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 31.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 12,105 shares of the biotechnology company’s stock after selling 5,523 shares during the quarter. Nuveen Asset Management LLC’s holdings in […]